2007
DOI: 10.1016/j.addr.2006.09.022
|View full text |Cite
|
Sign up to set email alerts
|

A cell cycle automaton model for probing circadian patterns of anticancer drug delivery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
45
0
2

Year Published

2007
2007
2017
2017

Publication Types

Select...
5
2
1

Relationship

3
5

Authors

Journals

citations
Cited by 60 publications
(50 citation statements)
references
References 34 publications
3
45
0
2
Order By: Relevance
“…30,40 Furthermore, chronotherapy theoretically should be more toxic to tumor cells because of poor circadian rhythm and greater cell cycle variability in malignant tissues compared with healthy tissues. 49 Although it has been demonstrated that HAI with irinotecan or oxaliplatin is not complicated by cholangitis, [20][21][22][23][24][25][26][27][28][29] it can be anticipated in as many as 30% of patients who receive HAI floxuridine. [46][47][48] This HAI chronotherapy regimen is well tolerated with no chemical bile duct sclerosis, whereas chronotherapy is not expected to decrease bile excretion of 5-FU metabolites.…”
Section: Discussionmentioning
confidence: 99%
“…30,40 Furthermore, chronotherapy theoretically should be more toxic to tumor cells because of poor circadian rhythm and greater cell cycle variability in malignant tissues compared with healthy tissues. 49 Although it has been demonstrated that HAI with irinotecan or oxaliplatin is not complicated by cholangitis, [20][21][22][23][24][25][26][27][28][29] it can be anticipated in as many as 30% of patients who receive HAI floxuridine. [46][47][48] This HAI chronotherapy regimen is well tolerated with no chemical bile duct sclerosis, whereas chronotherapy is not expected to decrease bile excretion of 5-FU metabolites.…”
Section: Discussionmentioning
confidence: 99%
“…The cell cycle automaton model reveals the key roles of variability in circadian entrainment and cell cycle length upon therapeutic activity of different sinusoidal delivery or constant-rate infusion schedules. This theoretical study pinpoints the need for novel biological assessments in the individual patient and his or her tumor in order to take full advantage of cancer chronotherapeutics (Altinok et al 2007). A pharmacokinetic-pharmacodynamic model of chemotherapy with circadian periodic dimension investigates the effects of temporal drug-delivery dynamics on a population of tumor cells and its tolerance by a population of fast-renewing healthy cells.…”
Section: Implications For Cancer Chronotherapeuticsmentioning
confidence: 99%
“…However, when the distribution of cells between the various cell cycle phases becomes the predominant issue, biochemical details do not play such a major role, and the automaton model provides a useful, versatile tool for describing the dynamics of a population of proliferating cells. Thus, we previously used the cell cycle automaton model to study the response of a population of proliferating cells to the circadian administration of an anti-cancer drug that acts on a particular phase of the cell cycle [17][18][19].…”
Section: Introductionmentioning
confidence: 99%